QuintilesIMS Introduces Orchestrated Customer Engagement (OCE)
June 26 2017 - 8:00AM
Business Wire
OCE Marks an Unprecedented Convergence in Sales
and Marketing SaaS Software
QuintilesIMS (NYSE:Q), a leading provider of information,
technology services and contract research to the life sciences
industry announced today the general availability of a new category
of pharmaceuticals commercial operations SaaS software called
Orchestrated Customer Engagement (OCE) in the winter of 2017.
This new category of enterprise SaaS software empowers
pharmaceutical commercial teams to better coordinate and streamline
several commercial functions. Those functions include;
multi-channel marketing, customer relationship management, medical
affairs, market access and home office operations, which can now
work together to deliver an orchestrated customer engagement
experience.
“Orchestrating our company’s engagement with our customers by
leveraging new technologies is an important part of our commercial
strategy,” said Chetak Buaria, Global Head of Commercial Excellence
(Biopharma), Merck KGaA, Darmstadt, Germany. “For this reason, we
are delighted to co-operate with QuintilesIMS on OCE. This
cooperation will give us the ability to influence the solution
roadmap and experiment new customer engagement models early
on.”
Merck KGaA, Darmstadt, Germany has been a QuintilesIMS
technology customer since 2013. And it looks forward to fully
benefiting from this unique OCE offering via deeper integration of
its sales and marketing functions while providing a more
orchestrated experience to its own customers.
This next generation of enterprise SaaS software is “born
integrated” on the latest versions of best-in-class technology
suppliers including: Force.com, Marketing Cloud, Heroku, Amazon Web
Services, Reltio and others. In addition to its seamless
integration across a “platform of platforms,” OCE leverages
QuintilesIMS’s Ada – an artificial-intelligence that provides users
with ambient, contextually appropriate, recommendations for the
next best customer, conversation, channel, content, colleague and
campaign.
The OCE offering also features Apollo – a thoughtfully-designed
user experience and interface that’s easy to use and understand; as
well as Lexi - an application program interface (API) layer that
connects all applications and data across an enterprise using
clear, common language. Customers can benefit from unprecedented
levels of integration, intelligent decision making as well as
optimal sales and marketing convergence with this revolutionary OCE
SaaS offering.
“We wanted to build a solution that fills the gaps in the
marketplace our customers were describing,” said Tal Rosenberg,
senior vice president, Global Technology Solutions, QuintilesIMS.
“This step-change evolution in enterprise SaaS software was created
with direct input from customers. That collaboration resulted in an
orchestrated commercial model that unifies several vertical silos
of disconnected sales and marketing operations --- creating
transformative, competitive offerings for our customers.”
For more information about Orchestrated Customer Engagement,
visit https://www.quintilesims.com/oce.
About QuintilesIMS
QuintilesIMS (NYSE:Q) is a leading integrated information and
technology-enabled healthcare service provider worldwide, dedicated
to helping its clients improve their clinical, scientific and
commercial results. Formed through the merger of Quintiles
Transnational and IMS Health, QuintilesIMS’s approximately 50,000
employees conduct operations in more than 100 countries. Companies
seeking to improve real-world patient outcomes through treatment
innovations, care provision and access can leverage QuintilesIMS’s
broad range of healthcare information, technology and service
solutions to drive new insights and approaches. QuintilesIMS
provides solutions that span clinical to commercial, bringing
customers a unique opportunity to realize the full potential of
innovations and advanced healthcare outcomes.
As a global leader in protecting individual patient privacy,
QuintilesIMS uses healthcare data to deliver critical, real-world
disease and treatment insights. Through a wide variety of
privacy-enhancing technologies and safeguards, QuintilesIMS
protects individual privacy while managing information to drive
healthcare forward. These insights and execution capabilities help
biotech, medical device and pharmaceutical companies, medical
researchers, government agencies, payers and other healthcare
stakeholders in the development and approval of new therapies, and
to identify unmet treatment needs and understand the safety,
effectiveness and value of pharmaceutical products in improving
overall health outcomes. To learn more, visit
www.QuintilesIMS.com.
Click here to subscribe to Mobile Alerts for
QuintilesIMS.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170626005393/en/
QuintilesIMS Media RelationsTor Constantino,
+1-484-567-6732tor.constantino@quintilesims.comorQuintilesIMS
Investor RelationsAndrew Markwick,
+1-973-257-7144andrew.markwick@quintilesims.com
IQVIA (NYSE:IQV)
Historical Stock Chart
From Apr 2024 to May 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From May 2023 to May 2024